{
    "2019-08-02": [
        [
            {
                "time": "",
                "original_text": "葫芦娃药业IPO：家族控股超8成 多项指标隐忧 业务推广费飙升244%",
                "features": {
                    "keywords": [
                        "葫芦娃药业",
                        "IPO",
                        "家族控股",
                        "业务推广费",
                        "飙升"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "健之佳：子公司资不抵债、亏损连连，新旧招股书数据不一 偿债能力下降",
                "features": {
                    "keywords": [
                        "健之佳",
                        "子公司",
                        "资不抵债",
                        "亏损",
                        "偿债能力"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药零售"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}